In one paragraphArticle in Journal of human immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
20 authors.
Mattison P StojcicDepartment of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, Canada.ORCID 0009-0006-3281-3921 Makenzie A ManningDepartment of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, Canada.ORCID 0009-0003-7020-2097 Manfred HönigDepartment of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany.ORCID 0000-0001-9165-1690 Despina MoshousPediatric Immunology, Hematology and Rheumatology Department, Necker-Enfants Malades University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.ORCID 0000-0001-6719-3693 Sven KrackerLaboratory of Lymphocyte Activation and Susceptibility to EBV Infection, INSERM UMR 1163, Imagine Institute, Université Paris Cité, Paris, France.ORCID 0000-0003-4543-8236 Felipe SuarezDepartment of Hématologie, Necker - Enfants Malades Hospital, Assistance Publique des Hopitaux de Paris (Institut IMAGINE INSERM U1163), Université Paris Cité, Paris, France.ORCID 0000-0002-3537-9052 Ruben Martinez-BarricarteDivision of Genetic Medicine and Clinical Pharmacology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-7925-449X Aidé Tamara Staines-BooneImmunology Service, Hospital de Especialidades Unidad Médica de Alta Especialidad, 25 del Instituto Mexicano del Seguro Social , Monterrey, México.ORCID 0000-0003-0776-8162 Yuridia Salazar GálvezImmunology Service, Hospital de Especialidades Unidad Médica de Alta Especialidad, 25 del Instituto Mexicano del Seguro Social , Monterrey, México.ORCID 0009-0009-1059-2971 Edgar-Domingo Cordero-ChuraPediatric Allergy and Immunology Department, Dr Ovidio Aliaga Uría Children's Hospital, La Paz, Bolivia.ORCID 0009-0002-3770-7459 Estefany-Graciela Mamani-VelasquezPediatric Allergy and Immunology Department, Dr Ovidio Aliaga Uría Children's Hospital, La Paz, Bolivia.ORCID 0000-0001-7122-9134 Jian CuiDivision of Genetic Medicine and Clinical Pharmacology, Department of Medicine, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-8483-9975 Jeremie RosainStudy Center for Primary Immunodeficiencies, Necker Hospital for Sick Children, Assistance Publique Hôpitaux de Paris , Paris, France.ORCID 0000-0002-2822-161X Pandiarajan VigneshPediatric Allergy Immunology Unit, Department of Pediatrics, Post Graduate Institute of Medical Education and Research, Chandigarh, India.ORCID 0000-0001-8490-5584 Sergio D RosenzweigImmunology Service, Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-5550-9678 Catherine M BiggsDepartment of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, Canada.ORCID 0000-0002-4363-2660 Jacob RozmusDepartment of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, Canada.ORCID 0000-0003-4036-2105 Stuart E TurveyDepartment of Pediatrics, BC Children's Hospital, The University of British Columbia, Vancouver, Canada.ORCID 0000-0003-1599-1065 Funding
Agence Nationale de la Recherche ANR-10-IAHU-01Agence Nationale de la Recherche ANR-19-CE17-0012BC Children's Hospital FoundationCentre National de la Recherche ScientifiqueCIHR DTA-210441CIHR OGB-205728CIHR PJT-178054Genome British Columbia SIP007INSERMJeffrey Modell Foundation
6 · The paper itselfAbstract
IRF4 is a transcription factor within the interferon regulatory factor family that controls key aspects of lymphocyte differentiation and adaptive immunity. The heterozygous IRF4 p.Thr95Arg (p.T95R) variant affecting the DNA-binding domain was recently identified to cause a new inborn error of immunity, but the longitudinal clinical course and therapeutic implications remain incompletely defined. We performed detailed clinical characterization and follow-up of all 10 known patients. Each presented with early-onset combined immunodeficiency characterized by hypo- or agammaglobulinemia and marked susceptibility to opportunistic infections. Pulmonary disease was universal, and gastrointestinal involvement was associated with a more severe clinical course. Four patients underwent hematopoietic stem cell transplantation; two survived, and two died. Notably, both deaths occurred in patients transplanted in the setting of active infection. These findings define IRF4 p.T95R as a profound combined immunodeficiency with high infectious burden and demonstrate that disease severity and intervention timing may contribute to transplant outcomes, supporting early diagnosis and timely transplantation before uncontrolled infection.
What Socratic holds
Textmetadata
Read underepoch 390